CUSIP No. 762567105 Page 1 of 7 Pages
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Amendment No. 1)
Under the Securities Exchange Act of 1934
Ribozyme Pharmaceuticals, Inc.
_________________________________________________________________
(Name of Issuer)
Common Stock, $.01 par value
-----------------------------------------------------------------
(Title of Class of Securities)
762567105
_________________________________________________________________
(CUSIP Number)
Jeremy L. Curnock Cook John C. MacMurray, Esq.
Rothschild Asset Management Ltd. Reboul, MacMurray, Hewitt,
Five Arrows House Maynard & Kristol
St. Swithin's Lane 45 Rockefeller Plaza
London EC4N 8NR England New York, New York 10111
Tel. 44-171-623-1000 Tel. (212) 841-5700
_________________________________________________________________
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 16, 1997
_____________________________
(Date of Event Which Requires
Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the
following box [ ].
<PAGE>
CUSIP No. 762567105 Page 2 of 7 Pages
_________________________________________________________________
1) Name of Reporting Person International
S.S. or I.R.S. Identification Biotechnology
No. of Above Person Trust plc
_________________________________________________________________
2) Check the Appropriate Box (a) [ ]
if a Member of a Group (b) [ ]
_________________________________________________________________
3) SEC Use Only
_________________________________________________________________
4) Source of Funds WC
_________________________________________________________________
5) Check if Disclosure of
Legal Proceedings is Not Applicable
Required Pursuant to
Items 2(d) or 2(e)
_________________________________________________________________
6) Citizenship or Place
of Organization United Kingdom
_________________________________________________________________
Number of 7) Sole Voting 1,012,633 shares of
Shares Beneficially Power Common Stock, $.01
par value ("Common
Owned by Stock")
Reporting Person
________________________________________
8) Shared Voting
Power -0-
________________________________________
9) Sole Disposi- 1,012,633 shares of
tive Power Common Stock
________________________________________
10) Shared Dis-
positive Power -0-
________________________________________
11) Aggregate Amount Beneficially 1,012,633 shares of
Owned by Each Reporting Person Common Stock
_________________________________________________________________
12) Check if the Aggregate
Amount in Row (11)
Excludes Certain Shares
_________________________________________________________________
13) Percent of Class
Represented by 11.78%
Amount in Row (11)
_________________________________________________________________
14) Type of Reporting
Person CO<PAGE>
CUSIP No. 762567105 Page 3 of 7 Pages
Amendment No. 1 to Schedule 13D
Reference is hereby made to the statement on Schedule 13D
originally filed with the Securities and Exchange Commission on May 3, 1996
(the "Schedule 13D").
Item 1. Security and Issuer.
___________________
This statement relates to the Common Stock, $.01 par value (the
"Common Stock") of Ribozyme Pharmaceuticals, Inc., a Delaware corporation
(the "Issuer"). The principal executive offices of the Issuer are located
at 2950 Wilderness Place, Boulder, Colorado 80301.
Item 2. Identity and Background.
_______________________
(a) The undersigned hereby files this Schedule 13D on behalf of
International Biotechnology Trust plc, a corporation organized under the
laws of the United Kingdom ("IBT" or the "Reporting Person"). The name,
business address and occupation of each executive officer and director of
IBT is set forth on Schedule A hereto.
(b) The principal business of IBT is that of a publicly-traded
investment trust company.
(c) IBT's principal business address is Five Arrows House, St.
Swithin's Lane, London EC4N 8NR, England.
(d) Neither IBT nor any of the persons identified in this Item 2
has, during the last five years, been convicted in a criminal proceeding
(excluding traffic violations or similar misdemeanors).
(e) Neither IBT nor any of the persons identified in this Item 2
has, during the last five years, been a party to a civil proceeding of a
judicial or administrative body of competent jurisdiction and as a result
of such proceeding was or is subject to a judgment, decree or final order
enjoining future violations of, or prohibiting or mandating activities
subject to, federal or state securities laws or finding any violation with
respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration.
_________________________________________________
On October 16, 1997 IBT purchased 275,000 shares of<PAGE>
CUSIP No. 762567105 Page 4 of 7 Pages
Common Stock (the "Secondary Offering Shares") in an offering by the Issuer
of an aggregate 1,400,000 shares of Common Stock (the "Secondary
Offering"), which were registered under the Securities Act of 1933, as
amended, pursuant to a Registration Statement on Form SB-2 filed by the
Issuer with the Securities and Exchange Commission and declared effective
on October 16, 1997 (SEC Registration No. 333-34981). The purchase price
of the Secondary Offering Shares was $8.00 per share. The source of funds
for IBT's purchase was its working capital, or funds available for
investment.
On April 11, 1996 IBT purchased 200,000 shares of Common Stock
(the "IPO Shares") in the Issuer's initial public offering (the "IPO"). In
the IPO the Issuer offered an aggregate 2,000,000 shares of Common Stock
for sale to the public, which were registered under the Securities Act of
1933, as amended, pursuant to a Registration Statement on Form SB-2 filed
by the Issuer with the Securities and Exchange Commission and declared
effective on April 11, 1996 (SEC Registration No. 333-1908-B). The
purchase price of the IPO Shares was $10.00 per share. The source of funds
for IBT's purchase was its working capital, or funds available for
investment. In addition to the 200,000 shares of Common Stock that IBT
purchased in the IPO, 315,411 shares of Common Stock were issued to IBT
upon the closing of the IPO, pursuant to antidilution provisions of the
Series G Preferred Stock that it held prior to the IPO, which converted
into 222,222 shares of Common Stock (after a 9 to 1 reverse stock split).
Item 4. Purpose of Transaction.
______________________
IBT purchased the Secondary Offering Shares for investment
purposes.
IBT owned 222,222 shares of Common Stock prior to the IPO. IBT
acquired 315,411 shares of Common Stock for the purpose of antidilution
protection, and purchased the IPO Shares for investment purposes.
Item 5. Interest in Securities of the Issuer.
____________________________________
(a) Based on a total of 8,594,000 shares of Common Stock
outstanding after the completion of the Secondary Offering, IBT owns
1,012,633 shares of Common Stock, or approximately 11.78% of the Common
Stock outstanding.
(b) Except as described in Item 6 below, IBT has sole power to
vote or direct the voting of and to dispose or to direct<PAGE>
CUSIP No. 762567105 Page 1 of 7 Pages
the disposition of the shares of Common Stock referred to in paragraph (a)
above.
(c) Except as described in this statement, neither IBT nor any
of the persons identified in Item 2 above has effected any transaction in
the Common Stock in the past 60 days.
(d) No other person has the power to direct the receipt of
dividends on, or the proceeds from sales of, the shares of Common Stock
owned IBT.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings
or Relationships with Respect to
Securities of the Issuer.
Pursuant to a contractual agreement, IBT has engaged Rothschild
Asset Management Limited ("RAM") to act as its discretionary investment
manager. Pursuant to such agreement RAM manages the business and assets of
IBT, which includes the authority to make decisions regarding the
acquisition or disposition of portfolio securities by IBT and to exercise
any rights (including voting rights) with respect to such securities. IBT
has the right to terminate RAM's appointment as manager at any time if RAM
is not performing its duties as manager to the satisfaction of the Board of
Directors of IBT.
Item 7. Material to be Filed as Exhibits.
Not Applicable.
<PAGE>
CUSIP No. 762567105 Page 6 of 7 Pages
Signature
_________
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: October 31, 1997
INTERNATIONAL BIOTECHNOLOGY
TRUST PLC
By: /s/ Jeremy L. Curnock Cook
Director
<PAGE>
CUSIP No. 762567105 Page 7 of 7 Pages
SCHEDULE A
___________
EXECUTIVE OFFICERS AND DIRECTORS OF IBT
The business address of each person listed below is c/o
Rothschild Asset Management Limited, Five Arrows House, St. Swithin's Lane,
London EC4N 8NR, England. The occupation of each person listed below
refers only to his relationship to IBT.
Name Occupation Citizenship
____ __________ ___________
John M. Green-Armytage Chairman U.K.
Donald Cecil Deputy U.S.
Chairman
Gary M. Brass Director U.K.
Jeremy L. Curnock Cook Director U.K.
Peter B. Collacott Director U.K.
Stephen A. Duzan Director U.S.
James D. Grant Director U.S.
Howard E. Greene Director U.S.
Dennis M.J. Turner Director U.K.
